Figure legends
FIGURE 1 The differences in the spleen volume for each patient
after the first 3 months of ruxolitinib therapy start and in the
interval from 3 to 6 months of ruxolitinib therapy.
FIGURE 2 The differences in StfR concentration for each patient
after the first 3 months of ruxolitinib therapy start and in the
interval from 3 to 6 months of ruxolitinib therapy.
FIGURE 3 The differences in the RBC transfusion volume which is
required to maintain Hb at 11.0-12.0 g/L compared to baseline for each
patient after the first 3 months of ruxolitinib therapy start and in the
interval from 3 to 6 months of ruxolitinib therapy.
FIGURE 4 The differences in early erythrocyte progenitor count
in the bone marrow (for proerythroblasts and for erythroblasts) for each
patient after the first 3 months of ruxolitinib therapy start and in the
interval from 3 to 6 months of ruxolitinib therapy.